What is metabolic dysfunction-associated steatohepatitis?
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a chronic liver condition characterised by hepatic steatosis (fat accumulation in the liver), hepatocellular inflammation, and progressive fibrosis associated with metabolic syndrome. An emerging indication area for tirzepatide and based on phase 2 clinical data.
What the research literature says
MASH (metabolic dysfunction-associated steatohepatitis) is the inflammatory-fibrotic form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The condition is driven by metabolic dysfunction including obesity, insulin resistance, and type 2 diabetes; the hepatic steatosis is the substrate on which inflammation and progressive fibrosis develop.
The Loomba tirzepatide MASH-with-liver-fibrosis trial documented reductions in liver fat and improvements in fibrosis biomarkers (PMID 38856224). The Sanyal an investigational triple agonist MASLD phase 2a trial extended the framework into the triple-receptor-agonist context with reductions in liver fat content (PMID 38858523). The Gastaldelli SURPASS-3 MRI substudy characterised tirzepatide’s effects on liver fat content and abdominal adipose tissue (PMID 35468325).
The mechanistic framework: the multi-receptor incretin agonists drive weight reduction and improve underlying insulin resistance, both of which reduce the metabolic-dysfunction substrate that drives MASH progression. The direct effects on hepatic lipid metabolism via the GLP-1 and (f) glucagon receptor arms may contribute additionally.
Why this matters in research context
MASH matters in peptide-research contexts as an emerging clinical-indication area for the multi-receptor incretin agonist class. Researchers studying tirzepatide in metabolic-disease contexts may find the MASH-research framework relevant to protocol design — liver-fat-content measurement by MRI proton density fat fraction is a well-characterised endpoint that anchors several published trials.
Related compounds
- Tirzepatide 10mg — MASH phase 3 development
Related research questions
References
- Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Lancet Diabetes Endocrinol 2022;10(6):393-406. [PMID 35468325]
- Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 2024;391(4):299-310. [PMID 38856224]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.